[
  {
    "ts": null,
    "headline": "How Flat Sales, Higher EPS, and New Organoid Tools At Bio-Techne (TECH) Have Changed Its Investment Story",
    "summary": "Bio-Techne Corporation recently reported past second-quarter and six-month results to December 31, 2025, with sales essentially flat year-on-year at about US$295.88 million for the quarter and US$582.43 million for the half, while net income and earnings per share from continuing operations increased modestly and the Board affirmed a quarterly dividend of US$0.08 per share. Alongside the earnings, Bio-Techne expanded its research tools portfolio with launches in synthetic hydrogels for 3D...",
    "url": "https://finnhub.io/api/news?id=b8e8118fc81c04b1b939806c8e4b7211803188d018c9bf72d53aa76be5fa8ae3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770631827,
      "headline": "How Flat Sales, Higher EPS, and New Organoid Tools At Bio-Techne (TECH) Have Changed Its Investment Story",
      "id": 138401318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne Corporation recently reported past second-quarter and six-month results to December 31, 2025, with sales essentially flat year-on-year at about US$295.88 million for the quarter and US$582.43 million for the half, while net income and earnings per share from continuing operations increased modestly and the Board affirmed a quarterly dividend of US$0.08 per share. Alongside the earnings, Bio-Techne expanded its research tools portfolio with launches in synthetic hydrogels for 3D...",
      "url": "https://finnhub.io/api/news?id=b8e8118fc81c04b1b939806c8e4b7211803188d018c9bf72d53aa76be5fa8ae3"
    }
  }
]